UBS O'Connor’s CytomX Therapeutics CTMX Stock Holding History

UBS O'Connor’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-259,965	Closed	-$335K	–	530
2023 Q3	$335K	Hold	259,965	–	–	0.01%	429
2023 Q2	$447K	Buy	259,965 +12,808	+5%	+$21.3K	0.01%	453
2023 Q1	$373K	Buy	+247,157	New	+$559K	0.01%	485

Other funds holding CTMX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BCM

Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

UBS O'Connor's CTMX Position: Q4 2023 in Review

UBS O'Connor sold out of CytomX Therapeutics (CTMX) in Q4 2023, closing a stake of 259,965 shares — an estimated $335K sold.

UBS O'Connor first reported a position in CTMX in Q1 2023 and held it in 3 quarters. The position peaked at $447K in Q2 2023. 68 funds tracked by Wall St. Rank hold CTMX as of Q4 2023.

UBS O'Connor reported no remaining CytomX Therapeutics position as of Q4 2023 after selling out during the quarter.
UBS O'Connor sold 259,965 CytomX Therapeutics shares in Q4 2023, an estimated $335K.
UBS O'Connor first reported a position in CytomX Therapeutics in Q1 2023 and held it in 3 quarters.
UBS O'Connor's CytomX Therapeutics position peaked at $447K in Q2 2023.
68 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2023.

Based on UBS O'Connor's 13F filing for Q4 2023, filed 14 Feb 2024.